Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423657 · ClinicalTrials.gov registry record · Phase 3
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
A Phase 3 study of Bacterial Infections, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 680
- Enrollment target
- 20
- Study locations
NCT00423657: Completed Phase 3 study of Bacterial Infections, sponsored by Forest Laboratories.
NCT00423657 is a Phase 3 study of Bacterial Infections that has completed, run by Forest Laboratories. The registered enrollment target is 680 participants, above the 101-participant average among 17 other Bacterial Infections trials with a reported enrollment target (573% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00423657, a Phase 3 study of Bacterial Infections, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 680 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.
Primary Outcome
Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of complicated skin and skin structure infection (cSSSI) due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis afte
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ceftaroline
- DRUG vancomycin plus aztreonam
Study Locations (20)
California
- Investigational Site - Buena Park
- Investigational Site - Hawaiian Gardens
- Investigational Site - Los Angeles
- Investigational Site - Pasadena
- Investigational Site - San Diego
- Investigational Site - San Jose
Other
- Investigational Site - Buenos Aires
- Investigational Site - Córdoba
- Investigational Site - Santa Fe
Georgia
- Investigational Site - Columbus
- Investigational Site - Marietta
Florida
- Investigational Site - Atlantis
Illinois
- Investigational Site - Springfield
Maryland
- Investigational Site - Baltimore
Minnesota
- Investigational Site - Minneapolis
Montana
- Investigational Site - Butte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00423657 record still lists
NCT00423657 is an interventional study that assigns participants to a tested intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, above the 101-participant average among 17 other Bacterial Infections trials with a reported enrollment target (573% higher).
The record links to 1 condition, with Bacterial Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00423657 names 20 study sites across 12 states, led by California, Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT00423657 about?
NCT00423657 is a clinical study titled "Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections". The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.
What is the current status of trial NCT00423657?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2007-03. Estimated completion is 2007-12.
What conditions does trial NCT00423657 study?
This clinical trial studies the following conditions: Bacterial Infections.
What interventions are being tested in trial NCT00423657?
The interventions under investigation include: Placebo (DRUG), ceftaroline (DRUG), vancomycin plus aztreonam (DRUG).
Who is sponsoring clinical trial NCT00423657?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00423657 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00423657's enrollment target sits among peer trials
680 1st of 17 higher than 17 of 17 other Bacterial Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacterial Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RECRUITING · Phase 3
-
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
COMPLETED · Phase 3
-
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
RECRUITING · Phase 1
-
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
RECRUITING · Phase 1
-
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia